Welcome to our dedicated page for Stereotaxis SEC filings (Ticker: STXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Stereotaxis, Inc. filings document an operating medical-technology company focused on robotic systems and instruments for minimally invasive endovascular intervention. Recent Form 8-K reports record operating and financial results, product and regulatory information included in earnings materials, and material-event disclosures.
The company’s SEC record also includes a definitive proxy statement covering annual-meeting and shareholder voting matters, governance, executive compensation, and director elections. Capital-structure filings describe common stock, shelf registration use, and an at-the-market sales agreement for working capital, research and development, and commercialization of the company’s innovation pipeline.
Stereotaxis, Inc. (STXS) reports that investor Daniel Louis Kaufman has filed a Schedule 13G disclosing a significant ownership position in its common stock. Kaufman beneficially owns 5,956,714 shares of Stereotaxis common stock, representing 5.9% of the outstanding shares.
His ownership is based on 100,202,178 shares outstanding as of July 31, 2026, as reported by Stereotaxis in its Form 10-Q for the quarter ended June 30, 2026. Kaufman has sole voting and sole dispositive power over all 5,956,714 shares, with no shared voting or dispositive power.
Stereotaxis, Inc. is registering for resale up to 108,868,331 shares of common stock held by existing investors. The shares consist of up to 72,722,177 shares issuable upon conversion of Series A Convertible Preferred Stock and up to 36,146,154 shares from related warrants. The company will not receive proceeds from these stockholder sales. The Series A Convertible Preferred carries a 6.0% cumulative, non-cash dividend that increases its conversion amount, adding to potential dilution.
The prospectus also describes the completed acquisition of Robocath for approximately $20.0 million in cash and stock plus up to $25.0 million in milestone-based earnouts, partly payable in shares subject to a 19.9% NYSE American share cap. Stereotaxis states the Robocath deal will not be accretive in the near term and is expected to increase consolidated operating losses while integration, manufacturing scale-up, and regulatory efforts proceed.
Stereotaxis, Inc. is registering up to 19,449,603 shares of common stock for resale by former Robocath securityholders and Robocath’s advisor. These shares include 6,269,628 Closing Shares already issued and up to 13,179,975 Earnout Shares that may be issued if specified regulatory and commercial milestones are achieved.
The earnout pool supports up to $25.0 million of contingent consideration and is subject to a 19.9% NYSE American Share Cap based on shares outstanding before the acquisition. Stereotaxis will not receive proceeds from these resales, other than de minimis cash from exercises of low‑priced Purchaser Warrants.
Stereotaxis, Inc. reported lower sales and higher losses for the six months ended June 30, 2026. Total revenue was $13.96 million, down from $16.27 million a year earlier, as systems revenue declined to $2.80 million from $5.00 million, while disposables, service and accessories were roughly flat at $11.16 million.
Gross margin was $8.28 million versus $8.64 million, but operating expenses rose slightly to $18.83 million, driving an operating loss of $10.55 million and a net loss of $10.33 million (net loss attributable to common stockholders $10.95 million). Cash used in operating activities was $7.12 million in the first half.
Cash and cash equivalents were $10.49 million at June 30, 2026, down from $13.42 million at year-end, partly offset by $5.3 million of net proceeds from an at-the-market equity program. The company continues to accumulate deficits (accumulated deficit $593.7 million) and expects additional losses as it invests in R&D, commercialization, and newly acquired operations.
Strategically, Stereotaxis is transitioning from third-party J&J catheters to its own MAGiC ablation catheter, which received FDA 510(k) clearance in January 2026, and advancing the MAGiC Sweep mapping catheter, cleared in July 2025. On July 7, 2026, it closed the acquisition of Robocath for roughly $20 million in cash and stock, with up to $25 million in potential earnouts, expanding into mechanical robotics for interventional cardiology and neurointerventions.
Stereotaxis, Inc. reported 2026 second quarter results with total revenue of $7.7 million for the quarter ended June 30, 2026, compared with $8.8 million a year earlier. System revenue was $1.5 million, down from $3.0 million in the prior-year quarter, reflecting the absence of a robotic system delivery, partially offset by initial Synchrony digital operating room sales. Recurring revenue from disposables, service, and accessories was $6.2 million, up from $5.8 million, supported by new robotic catheter contributions.
Gross margin was 58% of revenue. Operating expenses were $9.1 million, including $2.5 million of non-cash items, resulting in an operating loss of ($4.6) million and a net loss of ($4.5) million, compared with ($3.8) million a year earlier. Cash and cash equivalents were $10.5 million with no debt at June 30, 2026, and negative free cash flow was ($3.7) million.
The company highlighted that robotic catheter revenue surpassed $1 million with 270% sequential growth, reported the first U.S. GenesisX system purchase, multiple Synchrony installations following April FDA clearance, and completion of the Robocath acquisition. Management expects recurring revenue of approximately $7 million in the third quarter and $8 million in the fourth quarter, system revenue of about $3 million in each quarter, and anticipates reaching cash flow profitability in the first half of 2027.
Stereotaxis, Inc. reports that on July 7, 2026 it completed the acquisition of Robocath, obtaining 100% of its share capital and voting power. The company describes extensive integration, operational, regulatory, labor and tax risks as it assumes Robocath’s complex robotic systems and disposable products business.
At closing Stereotaxis issued 6,269,628 common shares, including 225,000 shares to Robocath’s financial advisor, and had extended $1.1 million of operating loans between signing and closing that were repaid and reduced upfront stock consideration. The Share Sale Agreement provides for up to $25 million in milestone-based earnout payments, payable in cash, Earnout Shares or Purchaser Warrants. Stereotaxis elected to register 13,179,975 Earnout Shares, with total Closing and Earnout Shares capped at 19.9% of shares outstanding as of July 7, 2026, creating the potential for significant dilution if milestones are met. Management states the Robocath acquisition will not be accretive initially and will increase operating losses and negatively impact consolidated results in the near term.
Stereotaxis, Inc. is registering 108,868,331 shares of common stock for resale by existing investors. The shares consist of up to 72,722,177 shares issuable upon conversion of Series A Convertible Preferred Stock, which carries a 6.0% cumulative dividend paid in stock, and 36,146,154 shares issued upon exercise of related warrants.
The company will not sell any securities or receive proceeds from these resales, having previously raised $24 million in the 2016 preferred-and-warrant financing and approximately $10.0 million plus $0.8 million from warrant exercises. As of June 30, 2026, 97,934,076 common shares were outstanding.
The filing also describes the July 2026 acquisition of French robotics firm Robocath for approximately $20.0 million in cash and stock, plus up to $25.0 million of milestone-based earnout consideration, payable in cash, shares or Purchaser Warrants, subject to a 19.9% share cap. Stereotaxis further highlights potential dilution from preferred stock, earnout shares and a $100.0 million universal shelf with an associated $50 million at-the-market facility.
Stereotaxis, Inc. is registering up to 19,449,603 shares of common stock for resale by Robocath securityholders and Robocath’s financial advisor, including 6,269,628 Closing Shares and up to 13,179,975 Earnout Shares linked to future milestones. Stereotaxis is not selling shares and will receive no resale proceeds, other than de minimis cash if $0.001 Purchaser Warrants are exercised.
The shares stem from the July 7, 2026 acquisition of Robocath, a French robotic-intervention company, completed for approximately $20.0 million in cash and stock plus up to $25.0 million in contingent earnouts. Combined Closing and Earnout Shares are capped at 19.9% of pre‑closing common stock, limiting share issuance but creating potential dilution and resale overhang, partly moderated by volume limits and European Investment Bank priority rights under a Resale Organization Agreement. Stereotaxis designs and sells robotic magnetic navigation systems and related technologies for minimally invasive cardiac and other endovascular procedures.